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Poster Session II 165of the treatment are. The content domain of a patient-reported in-
strument to measure the symptom burden of cGVHD should in-
clude questions about the severity of numerous symptoms and
how those symptoms have interfered with normal functioning.
Symptom burden should be measured longitudinally to capture
changes in symptom burden over time. Clinicians caring for pa-
tients with cGVHD should reduce uncertainty as much as possible
by offering clear explanations and should support patients in appro-
priate efforts at self-care to relieve symptoms.PHARMACY467
CLONAZEPAM PLUS LEVETIRACETAM (CL) FOR THE PREVENTION OF
BUSULFAN-INDUCED SEIZURES: A SINGLE CENTER EXPERIENCE
Bubalo, J.S.1, Kovascovics, T.J.1, Meyers, G.1, Mauro, M.1, Epner, E.1,
Hayes-Lattin, B.1, Deininger, M.1, Curtin, P.T.2, Leis, J.F.3,
Maziarz, R.T.1. 1 Oregon Health & Science University Hospital, Port-
land, OR; 2 University of California San Diego, San Diego, CA; 3 Mayo
Clinic, Phoenix, AZ.
High dose busulfan (.1 mg/kg) used in hematopoietic stem cell
transplant (HSCT) conditioning regimens is associated with a de-
crease in seizure threshold which can result in partial or generalized
seizures in up to 10% of people without a previous seizure history.
Phenytoin is the most frequently used agent to prevent seizures.
Though this is an effective therapy, the frequent side effects and sig-
nificant risk for drug interactions from phenytoin make it a subopti-
mal agent for this purpose. Also there is no preferred anti-seizure
prophylaxis for phenytoin allergic or intolerant patients. A retro-
spective review was performed of a single center experience using
CL in 46 consecutive patients receiving a variety of inpatient and
outpatient busulfan-containing regimens to assess it for side effects
and efficacy. The patients received the CL regimen over a 13month
period beginning July, 2006. Clonazepam 0.5 mg and levetiracetam
500mg where given together orally twice daily, beginning the even-
ing before busulfan therapy initiated until discontinuation on the
morning after the final busulfan dose was given. All patients were
adults, 20 female/26 male, aged 22–75 years, (mean 52, median 56
y/o), weight 54–113 kg (Mean and median 82 kg), with no prior his-
tory of seizures. They received HSCT conditioning regimens con-
taining oral (PO) busulfan 1 mg/kg/dose  12–16 doses, or
intravenous (IV) busulfan 3.2 mg/kg/day  1–3 days as part of the
following regimens: 5 - busulfan (12 mg/kg PO)/melphalan(100
mg/m2)/thiotepa 500 mg/m2), 4 - busulfan (9.6 mg/kg IV)/melpha-
lan(100 mg/m2)/thiotepa 500 mg/m2), 20 - busulfan (16 mg/kg)
PO/cyclophosphamide (120 mg/m2), and 16 - busulfan 3.2 mg/kg
IV/fludarabine (120 mg/m2/TBI (200 cGy). The regimen was com-
pletely successful with no patients experiencing any type of seizure
within 48 hours of their last dose of busulfan. Side effects were mild:
2 patients reporting mild sedation and 1 patient had their levetira-
cetam dose reduced to 250 mg twice daily for confusion. When
compared to the prior 104 patients receiving the same variety of
conditioning regimens with phenytoin anti-seizure prophylaxis,
fewer side effects were seen, with equal anti-seizure benefits and
a limited risk for drug interactions using the CL regimen. The
CL regimen is now the preferred therapy for busulfan seizure pro-
phylaxis for the transplant center.468
METHOTREXATE AND PIPERACILLIN/TAZOBACTAM VERSUS METHO-
TREXATE AND CEFTAZIDIME: A LOOK AT TIME TO ENGRAFTMENT
AND SIDE EFFECT PROFILE DIFFERENCES IN HEMATOPOIETIC STEM
CELL TRANSPLANT PATIENTS
Hoffmann, P.D., Haight, A.E. Children’s Healthcare of Atlanta, At-
lanta, GA.
Many HSCT patients receive methotrexate for GVHD prophy-
laxis. Commonly, methotrexate is given on days 11, 13, 16, and
variably 111. Most patients develop fever during this time period
and empiric antibiotics are started.In June 2006, our institution’s SOP changed the empiric antibi-
otic for fever from ceftazidime to piperacillin/tazobactam. Penicil-
lin derivatives interact with antineoplastic doses of methotrexate by
competing for renal tubular binding sites. Methotrexate toxicity
may include severe mucositis, marrow suppression, renal dysfunc-
tion, and hepatotoxicity. Smaller doses of methotrexate, like those
used for GVHD prophylaxis, have not been investigated. We eval-
uated side effects in patients who may have prolonged methotrexate
exposure caused by piperacillin/tazobactam co-administration.
We examined 36 patients over two years who receivedmethotrex-
ate for GVHD prophylaxis, comparing patients who received ceph-
alosporins with those receiving piperacillin/tazobactam. The
cephalosporin group included 23 patients (14 females, 9 males),
from July 1, 2005 to June 30, 2006. Average time to engraftment
(the first of three consecutive days with ANC . 500) was 18.25
(range 12–22) days for matched unrelated donor (MUD) trans-
plants, 11.9 (9–20) for matched sibling (MS) transplants, and
16.33 (14–19) for mismatched related transplants; overall average
for this group was 16.04 days to engraft. The piperacillin/tazobac-
tam group included a total of 13 patients (11 males, 2 females), from
July 1, 2006 to June 30, 2007. MUD transplants averaged 20.2 (16–
23) days, and MS transplants 17.4 (15–22); overall average was 18.7
days to engraft. Average days antibiotics overlapped methotrexate
was 6.17 and 5.46 for cephalosporin and piperacillin/tazobactam
groups, respectively. No significant differences in transaminases,
bilirubin, and serum creatinine were noted.
In summary, only a difference in time to engraftment was found,
with the piperacillin/tazobactam group taking 2.66 days longer.
This study is limited by small sample size and potential confounding
variables. Mucositis severity could not be compared in this retro-
spective study, but would be of interest for future studies. Based
on this small, retrospective single institution study, we conclude
that a major interaction between small doses of methotrexate and
piperacillin/tazobactam is not seen.469
HIGH RATE OF REVACCINATION IN ALLOGENEIC AND EARLY AUTOLO-
GOUS STEM CELL TRANSPLANTATION—RESULTS OF A SINGLE CENTER
COMPLIANCE TRACKING SURVEY
West, K., Brown, K., Paplham, P., Privitere, L., Syta, M.,
Battiwalla, M., Smiley, S., McCarthy, P.L. Roswell Park Cancer Insti-
tute, Buffalo, NY.
Background:Hematopoietic stem cell transplants (HSCT) have
increased over the past 25 years. With improving HSCT outcomes,
the number of long-term survivors has grown. HSCT recipients
lose their memory immune response against common vaccine-pre-
ventable infections and suffer from life-threatening late infectious
complications. Revaccination is an important strategy for reducing
the risk of preventable infections after HSCT. Materials and
Methods: After the implementation of an annual post transplant
clinic, compliance with revaccination recommendations of the In-
fectious DiseaseWorking Party of the EBMT (BMT 2005) was an-
alyzed. Initially letters were sent to patients greater than 1 year post
transplant inviting them to visit the clinic. The goal of the annual
clinic was to educate HSCT recipients, identify complications,
and recommend therapy for long-term post-transplant issues. Pa-
tients were encouraged to bring their immunization records to their
appointments. Data were collected from January 2006 until August
2007 utilizing patient histories and computer data base documenta-
tion tools for the clinic. Schedules were generated based on the rec-
ommendations of the Infectious Diseases Working Party of the
EBMT. Results: 42 subjects, 27 autologous and 15 allogeneic, at-
tended annual clinic during this time period. 27 patients had initi-
ated the recommended vaccination schedule and/or elected to
start or continue the re-immunization schedule after attending
the clinic. Fifteen patients declined vaccinations (11 autos and 4 al-
los) for various reasons including time out from transplant (median
10 years), 1 completed recommended series, 1 due to immunosup-
pressive therapy, and 1 with history of adverse reaction to vaccine
excipients. Patients declining full revaccination were encouraged
to maintain standard revaccinations such as yearly influenza shots
and ten year diphtheria/tetanus boosters. There were no toxicities
associated with revaccination. Conclusion: Education and
166 Poster Session IIimplementation of post HSCT revaccination was well received by
patients. A high proportion of allogeneic and early autologous
HSCT recipients successfully underwent revaccination.470
SUCCESSFUL TECHNOLOGICAL IMPLEMENTATION AT AN INNER CITY
MEDICAL CENTER
Robinson, N.1, Dumercy, D.2, Simon, N.1, Willumsen, S.2, Roberts, S.1,
Barredo, J.2, Kleiner, G.2. 1 Jackson Memorial Hospital, Miami, FL;
2 University of Miami Miller School of Medicine, Miami, FL.
Computerized order entry offers the potential of reducedmedical
errors arising from prescribing or administration. Our medical cen-
ter has recently rolled out a new computerized system. This system
does not provide chemotherapy specific ordering. The Pediatric
HSCT program at University of Miami/Jackson Holtz Children’s
Hospital has been utilizing a dedicated chemotherapy specific com-
mercially available system for outpatient chemotherapy prescribing
for the last four years. This system is one of the few computerized
systems available specifically for chemotherapy. We have recently
implemented computerized order entry for inpatient HSCT. Stan-
dardized order templates for chemotherapy (TBICY, BUCY,
CampFluMel, etc) were created in an attempt to diminish prescrib-
ing and administration errors. The protocols were flagged for high
alert medications (ganciclovir, neupogen, ATGAM) in an attempt
to diminish administration errors (protocol violations). A nursing
flowsheet and extensive nursing in-servicing was implemented si-
multaneously. Since implementation in the inpatient setting we
have observed significantly fewer deviations. Novel technologies
have the potential to diminish medical errors and improve overall
patient care.PHARMACY ORAL471
AN APREPITANT CONTAINING REGIMEN CONTROLS THE DELAYED
NAUSEA AND VOMITING ASSOCIATED WITH HIGH-DOSE MELPHALAN
FOLLOWED BY AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANS-
PLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
Bechtel, T.P.1, Crawford, B.S.1, Gordon, S.M.2, Penza, S.3,
Hofmeister, C.3, Benson, D.3, Devine, S.3. 1 Arthur G James Cancer Hos-
pital and Richard J Solove Research Institute at The Ohio State University
Medical Center, Columbus, OH; 2 Richard L Roudebush VA Medical
Center, Indianapolis, IN; 3 Arthur G James Cancer Hospital and Richard
J Solove Research Institute at The Ohio State University Medical Center,
Columbus, OH.
Background: Aprepitant is approved for the prevention of acute
and delayed nausea and vomiting associated with highly emetogenic
chemotherapy. It has not, however, been studied in patients receiv-
ing high-dose melphalan prior to an autologous peripheral blood
stem cell transplantation (PBSCT). Objective: The principal ob-
jective was to determine the ability of an aprepitant containing reg-
imen to prevent delayed vomiting 24–120 hours after the
administration of high-dose melphalan followed by an autologous
PBSCT in patients with multiple myeloma (MM). Methods: The
study period was from days -1 through 13. Eligibilty criteria in-
cluded: age.18 years, diagnosis of MM undergoing an autologous
PBSCT utilizing melphalan as the preparative regimen and serum
aminotransferases and t. bilirubin \2 upper limit of normal.
Twenty-five patients received a melphalan dose of 200 mg/M2
and one received 140 mg/M2 on day -1. Treatment consisted of
aprepitant 125 mg orally d -1 followed by 80 mg orally for 2 days
(days 0 and 11); ondansetron 16 mg orally d -1: dexamethasone
12 mg orally d -1 followed by 8 mg daily orally for 3 days (days
0 to 13) with breakthrough medications as needed. Patients were
evaluated for the frequency of emetic episodes, the need for break-
through antiemeticmedication and themeannausea score in 24hour
increments beginning 24 hours after treatment and continuing until
120 hours. The nausea score was determined using a linear analog
scale (0–10). A complete response was defined as no more than one
emetic episode during the evaluation period. Results: A total of 26
patients (17 male, 9 female) were enrolled in the study. Of these pa-
tients, 25 (96%) were complete responders and 24 (92%) had nodocumented emetic episodes during the study period. One patient
(4%) had 1 emetic episode and 1 patient (4%) had 2 emetic episodes.
Some degree of nausea was reported by 23 of 26 patients and the
mean nausea score for the entire group over the study period was
0.7 (range 0–10). All but 3 patients required some breakthrough an-
tiemetic therapy, primarily with promethazine. When compared
with historical results, the aprepitant containing regimen provided
better control than palonosetron alone, ondansetron alone or on-
dansetron/dexamethasone.Conclusion:This aprepitant containing
regimen appeared to control the delayed nausea/vomiting associ-
ated with high-dose melphalan in the PBSCT setting and has now
become the standard of practice in this group at our institution.472
PRE-TRANSPLANT BUSULFAN TEST DOSE IS A RELIABLE ALTERNATIVE
TO FIRST BUSULFAN IV DOSE FOR PHARMACOKINETICS STUDIES IN AL-
LOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Beri, R., Chunduri, S., Mactal-Haaf, C., Sweiss, K., Dobogai, L.,
Hurter, B., Shord, S., Peace, D., Rondelli, D. University of Illinois, Chi-
cago, IL.
In this study we tested the efficacy of a test dose of IV busulfan in
targeting blood levels of this drug during the conditioning regimen
prior to an allogeneic hematopoietic stem cell transplant. We ana-
lyzedblood samples of 23patientsundergoing allogeneic hematopoi-
etic stem cell transplantation with a busulfan-based conditioning
regimen. Patients received a test dose of busulfan at 0.8 mg/kg as
a 60 minute intravenous infusion. Serial blood samples were drawn
at eight time points- from 15 minutes before dose to 6 hours after
dose completion. Pharmacokinetics (PK) studies were then per-
formed at the Seattle Cancer Care pharmacokinetics laboratory.
The AUC was determined usingWinNonlin Professional software.
The conditioning dose of busulfan was calculated by multiplying
the test dose in mg/AUC  4800. After the first conditioning dose
of busulfan was administered, the same procedure was repeated to
test busulfan PK. If the busulfan AUC was therapeutic (between
4800 mM*min and 5200 mM*min) then the same dose was continued,
otherwise the third and fourth doses of busulfan were adjusted pro-
portionally.
The test dose of 0.8 mg/kg intravenous did not have any hemato-
logical side effects. The mean historic dose (solely based on weight)
was 3.2 6 0.1 mg/kg and the mean dose based on the test dose was
3.56 0.5 mg/kg (p5 0.02). In 17 patients we also analyzed PK after
the first day of conditioning regimen. AUC values of busulfan calcu-
lated from test dose and from day 1 dose were not different (p 5
0.15). The mean dose of busulfan based on test dose was 3.5 6
0.5 mg/kg while the final dose based on day 1 busulfan PK was
3.66 0.7 mg/kg (p5 0.9). Two CML patients who were on dasati-
nib and nilotinib had unusually high AUCs of 6065 and 5920
mM*min respectively suggesting a possible drug interacation be-
tween busulfan and tyrosine kinase inhibitors. Our study suggests
that pre-transplant busulfan test dose reliably predicts the actual
conditioning dose and can be safely utilized to target desirable AUC.
Test dose of busulfan can be conveniently performed anytime be-
fore transplant and therefore can safely replace the first dose PK at
centers where quick busulfan assay cannot be performed.473
RABBIT ATG (THYMOGLOBULIN R) PHARMACOKINETICS IN PEDIATRIC
PATIENTS RECEIVING AMATCHEDUNRELATED DONOR BONEMARROW
TRANSPLANTATION
Call, S.K., Kasow, K., Barfield, R., Leung, W., Madden, R., Horwitz, E.,
Woodard, P., Yusuf, U., Panetta, J.C., Baker, S., Handgretinger, R.,
Rodman, J., Hale, G.A. St. Jude Children’s Research Hospital, Memphis,
TN.
Objective:The pharmacokinetics of active and total rabbit ATG
(rATG) were determined in children with hematologic malignan-
cies receiving a matched unrelated donor (MUD) bone marrow
transplantation (BMT). Methods: 13 pediatric patients (n 5 13)
undergoing MUDHSCTwith a non T-cell depleted graft received
a conditioning regimen of 12 Gy TBI, thiotepa (5 mg/kg q12h  2
doses day-4) and cyclophosphamide (60 mg/kg  2 days -3, -2).
GVHD prophylaxis consisted of cyclosporine and methotraxate.
